Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation
(2006) In Allergy 61(3). p.298-302- Abstract
- Background: Monitoring of the allergen sensitivity of a patient is most important for optimal patient care and a basic prerequisite for immunomodulating treatment. The objective of this study was to investigate how basophil allergen sensitivity can be applied in the monitoring of anti-immunoglobulin E (IgE) treatment. Methods: Basophils from timothy grass pollen allergic patients were, by flow cytometry, analysed for allergen threshold sensitivity (CD-sens) by measuring CD63 up-regulation on CD203c-identified basophils. The results were compared with maximal percentage CD63 up-regulation at one allergen dose (CD-max), skin prick test end-point allergen titration, (SPT-sens), nasal provocation titration tests (nasal provocation titre) and... (More)
- Background: Monitoring of the allergen sensitivity of a patient is most important for optimal patient care and a basic prerequisite for immunomodulating treatment. The objective of this study was to investigate how basophil allergen sensitivity can be applied in the monitoring of anti-immunoglobulin E (IgE) treatment. Methods: Basophils from timothy grass pollen allergic patients were, by flow cytometry, analysed for allergen threshold sensitivity (CD-sens) by measuring CD63 up-regulation on CD203c-identified basophils. The results were compared with maximal percentage CD63 up-regulation at one allergen dose (CD-max), skin prick test end-point allergen titration, (SPT-sens), nasal provocation titration tests (nasal provocation titre) and serum IgE and IgE antibody concentrations. Results: There was a significant correlation (r = 0.50, P = 0.01) between CD-sens and SPT-sens, CD-sens and the IgE antibody concentration in percentage of 'total IgE' (relative IgE antibody concentration) (r = 0.72, P < 0.001) as well as between CD-sens and nasal provocation titre (r = 0.54, P < 0.05) but, in contrast, CD-max did not correlate with any of the sensitization parameters, i.e. SPT-sens, nasal provocation titre, absolute and relative IgE antibody concentration or CD-sens. CD-sens could be used to monitor omalizumab treatment efficacy while, based on CD-max, four of seven symptom-free patients on omalizumab would have been classified as having ongoing allergy. Conclusions: CD-sens seems to be very useful for the determination of a patient's allergen sensitivity and should be evaluated for the measurement and monitoring of anti-IgE treatment efficacy. CD-max, the conventional approach to basophil allergen challenge, which mirrors cell reactivity, gives incorrect information. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/419580
- author
- Nopp, A ; Johansson, SGO ; Ankerst, Jaro LU ; Bylin, G ; Cardell, Lars-Olaf LU ; Gronneberg, R ; Irander, K ; Palmqvist, M and Oman, H
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- omalizumab, immunoglobulin E, CD63, CD-sens, CD203c
- in
- Allergy
- volume
- 61
- issue
- 3
- pages
- 298 - 302
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:16436137
- wos:000234853900005
- scopus:33644903489
- pmid:16436137
- ISSN
- 1398-9995
- DOI
- 10.1111/j.1398-9995.2006.00987.x
- language
- English
- LU publication?
- yes
- id
- 5f110f19-8744-458d-88f8-4d0178ad97f6 (old id 419580)
- date added to LUP
- 2016-04-01 16:32:30
- date last changed
- 2024-01-11 09:37:48
@article{5f110f19-8744-458d-88f8-4d0178ad97f6, abstract = {{Background: Monitoring of the allergen sensitivity of a patient is most important for optimal patient care and a basic prerequisite for immunomodulating treatment. The objective of this study was to investigate how basophil allergen sensitivity can be applied in the monitoring of anti-immunoglobulin E (IgE) treatment. Methods: Basophils from timothy grass pollen allergic patients were, by flow cytometry, analysed for allergen threshold sensitivity (CD-sens) by measuring CD63 up-regulation on CD203c-identified basophils. The results were compared with maximal percentage CD63 up-regulation at one allergen dose (CD-max), skin prick test end-point allergen titration, (SPT-sens), nasal provocation titration tests (nasal provocation titre) and serum IgE and IgE antibody concentrations. Results: There was a significant correlation (r = 0.50, P = 0.01) between CD-sens and SPT-sens, CD-sens and the IgE antibody concentration in percentage of 'total IgE' (relative IgE antibody concentration) (r = 0.72, P < 0.001) as well as between CD-sens and nasal provocation titre (r = 0.54, P < 0.05) but, in contrast, CD-max did not correlate with any of the sensitization parameters, i.e. SPT-sens, nasal provocation titre, absolute and relative IgE antibody concentration or CD-sens. CD-sens could be used to monitor omalizumab treatment efficacy while, based on CD-max, four of seven symptom-free patients on omalizumab would have been classified as having ongoing allergy. Conclusions: CD-sens seems to be very useful for the determination of a patient's allergen sensitivity and should be evaluated for the measurement and monitoring of anti-IgE treatment efficacy. CD-max, the conventional approach to basophil allergen challenge, which mirrors cell reactivity, gives incorrect information.}}, author = {{Nopp, A and Johansson, SGO and Ankerst, Jaro and Bylin, G and Cardell, Lars-Olaf and Gronneberg, R and Irander, K and Palmqvist, M and Oman, H}}, issn = {{1398-9995}}, keywords = {{omalizumab; immunoglobulin E; CD63; CD-sens; CD203c}}, language = {{eng}}, number = {{3}}, pages = {{298--302}}, publisher = {{Wiley-Blackwell}}, series = {{Allergy}}, title = {{Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation}}, url = {{http://dx.doi.org/10.1111/j.1398-9995.2006.00987.x}}, doi = {{10.1111/j.1398-9995.2006.00987.x}}, volume = {{61}}, year = {{2006}}, }